In the last decade osteoporosis in men has become recognized as an important clinical and public health problem. As the magnitude and character of the issue became apparent, it also became clear to patients and their physicians that few data were available concerning its treatment. For some time patients with the disorder were managed by extrapolation from approaches used in women. More recently, therapies for osteoporosis have been specifically tested in men and their effectiveness has allowed the development of useful therapeutic strategies. At the same time, the obvious benefit derived from these advances must be tempered by the realization that the design principle underlying trials of therapies in men has been one of ''probable equivalency''-or the intent that small studies in men should be devised to generally duplicate favorable findings from previous, more definitive trials in women. In fact, that approach has apparently worked well (several drugs are now approved for use in osteoporotic men), but it has left a body of information concerning the therapy of osteoporosis in men that is a pale reflection of that in women, and in many clinical situations decisions can be made only by assuming that therapeutic results in men will be similar to those expected in women.
In the last decade osteoporosis in men has become recognized as an important clinical and public health problem. As the magnitude and character of the issue became apparent, it also became clear to patients and their physicians that few data were available concerning its treatment. For some time patients with the disorder were managed by extrapolation from approaches used in women. More recently, therapies for osteoporosis have been specifically tested in men and their effectiveness has allowed the development of useful therapeutic strategies. At the same time, the obvious benefit derived from these advances must be tempered by the realization that the design principle underlying trials of therapies in men has been one of ''probable equivalency''-or the intent that small studies in men should be devised to generally duplicate favorable findings from previous, more definitive trials in women. In fact, that approach has apparently worked well (several drugs are now approved for use in osteoporotic men), but it has left a body of information concerning the therapy of osteoporosis in men that is a pale reflection of that in women, and in many clinical situations decisions can be made only by assuming that therapeutic results in men will be similar to those expected in women.
Prevention-The Foundation for Any Therapeutic Regimen
Before considering approaches for the management of men afflicted with osteoporosis, it is important to recognize that lifestyle, diet, and the management of disorders known to affect bone health should be optimized. Of particular importance are limited alcohol consumption, smoking cessation, optimal dietary calcium and vitamin D intake, adequate and safe levels of exercise, and the recognition and treatment of secondary causes of osteoporosis. Without these measures, other treatment regimens cannot achieve good results. Although these basic considerations are not the subject of this review, their importance cannot be overemphasized.
Bisphosphonates
Bisphosphonate therapy has become a mainstay in the therapy of osteoporosis in men. Initially, the use of bisphosphonates in men was based on several small, uncontrolled observational studies and the presumption that their effectiveness would mirror that in women. However, in 2000 a larger, randomized, placebo-controlled trial of alendronate resulted in its approval for the treatment of men [1] . The essentials of the trial are important. The men recruited for the study varied widely in age (30-90 years) but in general were over age 60 years old, reflecting the fact that osteoporosis is primarily a disorder of older people. None of the subjects had an active secondary cause of osteoporosis, although men with low free testosterone levels were enrolled if they declined androgen therapy. Thus, other than a segment of men who may have experienced the detrimental skeletal effects of hypogonadism, this was an evaluation of the effects of alendronate in primary osteoporosis. Men with low BMD were included (hip or spine BMD T-score <)2.0; the T-scores were calculated from young normal male reference ranges). All men in the trial received calcium and vitamin D supplements and were randomized to receive either alendronate 10 mg/day or placebo for two years. Important end points in the study were BMD, height change, vertebral fracture, and safety. The drug was very well tolerated (the rate of adverse effects was similar to placebo), and BMD at the spine, hip, and total body were increased by alendronate to an extent very similar to that seen previously in studies of postmenopausal osteoporotic women. Height loss was reduced in the alendronate-treated group, and the rate of incident vertebral fractures (as assessed by quantitative vertebral morphometry) was considerably reduced. A semiquantitative assessment of vertebral fractures revealed very similar, although not statistically significant, results. About one-third of the men had a prevalent vertebral fracture at baseline, and most of the fractures during the trial occurred in these men taking placebo, suggesting that alendronate helps prevent recurrent fracture. There were few nonvertebral fractures during the trial and no conclusion can be drawn about the usefulness of alendronate in their prevention. The usefulness of alendronate in men with lesser degrees of osteopenia (BMD T-scores >)2.0) is unknown but the number needed to treat to prevent fractures is probably prohibitively high.
Importantly, those men who had low serum testosterone levels at the onset of the trial had BMD increases equivalent to those with normal testosterone levels, and neither serum testosterone nor estradiol was correlated with BMD change from alendronate treatment. In addition, older men responded similarly to younger men, and those with lower BMD responded similarly to those with less severe osteoporosis. There were too few men with hypogonadism to determine if the efficacy of alendronate in fracture risk reduction was affected by gonadal function.
More recently, additional trials of alendronate became available. For instance, Ringe et al. [2] compared the effects of alendronate to those of alphacalcidiol in the treatment of men with primary osteoporosis. Alendronate use was associated with an increase in BMD of similar magnitude to the study by Orwoll et al. [1] , and the rate of vertebral fracture was less than that observed in the group treated with alphacalcidiol. In a study by Weber et al. [3] , a retrospective review of men with low bone mass treated with alendronate or calcium/vitamin D for 2-3 years, those receiving alendronate had greater increases in hip and spine BMD than those treated more conservatively. In a randomized, placebo-controlled trial, Gonnelli et al. [4] found that BMD at the spine and hip and calcaneal ultrasound measures increased in a group treated with alendronate compared with the controls. That the response to alendronate is similar in men and women was reinforced by an observational study that included both men and women [5] . The increase in BMD was similar regardless of sex. Weekly administration of alendronate (70 mg) appears to be equivalent to once daily alendronate (10 mg) in men [6, 7] .
In combination, these results have appropriately been considered to demonstrate the usefulness of alendronate in improving BMD in men with idiopathic osteoporosis and in men with osteoporosis with low testosterone levels, and in reducing the risk of vertebral fracture in men with osteoporosis. By extrapolation, it has also been assumed that the risk of nonvertebral fracture is reduced in men as it is in women treated with alendronate [8] . On the basis of the gender similarities in BMD change and in vertebral fracture risk reduction, this is a reasonable, albeit untested, conclusion.
Although there is no reason to expect variations in the effectiveness of bisphosphonates in men, other compounds have not been as well examined in placebocontrolled trials in men. Preliminary data suggest that risedronate has positive effects on BMD and vertebral fracture risk in men [9] , and additional trials are underway with risedronate. Other bisphosphonates have not been adequately evaluated.
Bisphosphonates in the Treatment of Secondary Causes of Osteoporosis
Bisphosphonates have also been used in the prevention and treatment of two important secondary causes of osteoporosis in men-glucocorticoid excess and hypogonadism.
It is clear that bisphosphonates are effective in the prevention and treatment of glucocorticoid-induced bone loss. Although trials that have specifically targeted men with glucocorticoid-induced bone loss are not available, men have been included in mixed-patient populations randomized to receive placebo or a bisphosphonate [10] [11] [12] . Modest increases in BMD were observed in the treated men and were similar to those observed in premenopausal and postmenopausal women. The incidence of vertebral fractures is reduced in heterogeneous groups of men and women with glucocorticoid-induced osteoporosis treated with bisphosphonates [10] [11] [12] [13] . However, since there have been relatively few men included in those trials, and the fractures observed in either bisphosphonate-or placebo-treated were few in these short-term trials, there has been limited power to detect an antifracture effect in men. Nevertheless, the cumulative data suggest that bisphosphonates are useful in reducing vertebral fracture risk in men with glucocorticoid-induced osteoporosis.
Hypogonadism is an important cause of bone loss in men and effective preventative and therapeutic approaches to the problem are needed. As mentioned above, osteoporotic men with low serum testosterone levels appear to respond to alendronate as do those with normal gonadal function [1] . In addition, in a well-designed two-year trial, the rapid bone loss associated with the acute hypogonadism induced by GnRH agonist therapy of prostate disease was found, on average, to be completely abrogated by periodic pamidronate treatment [14] . Although the actions of other bisphosphonates have not yet been studied, there is no conceptual reason to suspect that they would not be effective in men with hypogonadism.
Parathyroid Hormone
Over the last several decades parathyroid hormone therapy has been used in a variety of small, uncontrolled studies of men with osteoporosis, with seemingly excel-lent effects on BMD. More recently, Kurland et al. [15] performed a randomized, placebo-controlled trial of parathyroid hormone 1-84 therapy in 23 men with idiopathic osteoporosis and demonstrated a rapid gain in BMD in association with an increase in markers of bone remodeling. This study was followed by a similar and larger trial of parathyroid hormone 1-34 in 437 men with osteoporosis (BMD T score <)2.0 or <)1 in the presence of a previous fragility fracture) [16] . Men with osteoporosis in the face of low serum testosterone levels were also included. Approximately one-third of the participants had prevalent vertebral deformities at baseline. Once again, a rapid increase in spinal BMD, with similar but less marked increases at the hip, were observed in response to treatment with PTH (20-40 lg/ day). There was a downward trend in radial BMD. The treatment was well tolerated, especially in the 20-lg group in which the rate of adverse effects was indistinguishable from placebo. Unfortunately, this trial was terminated prematurely (after a mean of 11 months of treatment) when a group of Fisher 344 rats treated with larger doses of PTH for long periods were found to develop osteosarcomas. After considerable debate and reconsideration, the experience in rats was considered unlikely to reflect a significant risk in humans treated with lower doses for brief periods, and PTH 1-34 (20 lg/day) is now available for the treatment of men with osteoporosis. As with bisphosphonates, the increase in BMD induced by PTH is as marked in those with low testosterone levels as in eugonadal men [16] , suggesting that PTH therapy should be effective in men with hypogonadism. Age, smoking, alcohol intake, or baseline BMD levels also did not appear to affect the therapeutic response. Men and women experience very similar increases in BMD in response to PTH treatment.
There were too few clinical fractures in the trials of PTH therapy in men to determine the effects of PTH therapy on fracture risk. However, after the trial of PTH 1-34 was discontinued, most of the men entered an 18-month observational study that involved measures of BMD and a final vertebral radiograph [17] . Spinal BMD gradually declined after PTH treatment was discontinued but it remained above baseline at the end of 18 months of observation. The increase in BMD that had been induced by PTH treatment in the proximal femur was maintained. Spinal radiographs at the end of the observational study were compared with those obtained at the onset of therapy to determine vertebral fracture rates. In the group treated with PTH, the rate of moderate to severe vertebral fractures was significantly lower, and the rate of less severe vertebral fractures were reduced, but not significantly so. When these results were compared with those from similar studies in women (treated with PTH and followed during an observational period thereafter), the reductions in vertebral fracture risk were essentially the same. These results strongly suggest that the benefits of PTH therapy in men (increases in BMD and reductions in fracture risk) are similar to those in women.
The usefulness of PTH therapy in men with glucocorticoid-induced osteoporosis has not been examined, but PTH treatment is beneficial in glucocorticoid-treated women [18] . In light of the gender similarities in responses to PTH in other situations (above), PTH treatment in men with glucocorticoid-induced osteoporosis should be useful. There are no data concerning the use of PTH in combination with testosterone in men.
The followup of men treated with PTH should be similar to that in women and should include periodic monitoring for adverse symptoms and elevated serum calcium levels. The recommended duration of parathyroid hormone therapy is currently two years. What therapeutic measures should be taken to optimize bone strength after that time is uncertain, but antiresorptive treatment following discontinuation of PTH may be useful to maintain or further enhance bone mass.
The potential usefulness of parathyroid hormone therapy in combination with a bisphosphonate has been of considerable interest. In a well-designed month long trial, Finkelstein et al. [25] compared the effects of alendronate alone, parathyroid hormone 1-34 alone, and a combination of the two therapies in men with low bone density who had not been previously treated for osteoporosis. Whereas who recieved alendronate alone or parathyroid hormone alone experienced changes in BMD and biochemical markers of bone remodeling similar to those reported in previous studies of those treatments, the group treated with the combination had increases in BMD and markers that were less than those treated with PTH alone and greater than those receiving alendronate alone. There were too few participants to assess the effects on fracture risk. These results are very similar to those reported in similar studies in women. There is less experience with sequential therapeutic regimens (PTH treatment preceded or followed by bisphosphonate administration). At present, the use of combination therapies in men remains of uncertain usefulness.
Sex Steroid Therapy of Hypogonadal Men
In hypogonadal men treated with testosterone the serum levels of both testosterone and estradiol can be restored to those of eugonadal men. A variety of trials have demonstrated that sex steroid replacement in men with well established hypogonadism is associated with an increase in BMD-most notably in the spine but also at more cortical sites [19] . In most cases, testosterone treatment is associated with a reduction in biochemical markers of bone remodeling, but in some reports an increase in markers of bone formation has been noted early (months 1-3) in the course of therapy [20] . In addition, an increase in lean mass and strength may accompany testosterone treatment, an effect that has been speculated to have positive effects not only on bone but also on the risk of falls. The effect of testosterone therapy on fracture risk is unknown.
Moreover, whereas most of the subjects included in the studies of the effects of testosterone noted were relatively young and had clearly established hypogonadism, a major clinical issue is the management of older men with low BMD who have modestly low testosterone levels, most probably a marker of the virtually universal age-related decline in gonadal function. There is much less information concerning the effects of testosterone therapy in those men. One carefully designed, placebocontrolled trial of transdermal testosterone replacement in older men with moderately lowered serum testosterone levels failed to find a clear benefit on spine or hip BMD [21] . However, in a similar trial in which a more intense treatment regimen was used (intramuscular testosterone at 2 week intervals) clear increases in BMD were achieved [26] . Treatment with different testosterone doses or routes of administration, or treatment of older men with lower baseline testosterone levels, could yield still more promising results. There is no information concerning the effect of androgen therapy on fracture risk in men.
Finally, there is insufficient information concerning the risk of testosterone therapy, especially in older men. Trials of testosterone treatment have enrolled men without evidence of significant prostate disease and have been of short duration ( £ 3 years). The effects of longerterm therapy on prostate health, or on other tissues, is unknown. In light of the limited data concerning the effectiveness of testosterone treatment of osteoporosis (especially its effects on fracture risk), the lack of information concerning adverse effects, and the availability of other safe treatments with demonstrated effectiveness in osteoporotic men with low testosterone levels, it is more appropriate to treat osteoporosis in hypogonadal men with a bisphosphonate or parathyroid hormone. Symptoms of hypogonadism (e.g., sexual dysfunction, fatigue, anemia, etc.) are reasonably treated with testosterone. It is unknown whether testosterone used in combination with a bisphosphonate or parathyroid hormone is of added benefit.
Estrogens clearly influence bone biology in men and may have more potent effects than androgens, especially in reducing bone resorption and preserving BMD. In rare men with aromatase insufficiency, estradiol treatment can have dramatically positive effects on bone mass [22] . At present, the usefulness of estradiol treatment of other men with osteoporosis is unknown, and the risks of estradiol therapy have not been explored. A small, short-term study of raloxifene suggested that biochemical indices of resorption may be reduced in those who entered the trial with the lowest estradiol levels [23[, but the usefulness of selective estrogen receptor modulators in men with osteoporosis has not been examined.
Other Therapies
Several other treatments have been suggested to be useful in osteoporotic men, including fluoride, vitamin D, and calcitonin. In fact, vertebral fracture risk has been reported to be reduced in men treated with fluoride [24] . Unfortunately, the experience with these approaches is very limited and it is difficult to be confident of their effectiveness. In some cases in which more established therapies are untenable (drug intolerance or contraindications), their use may be considered.
Selecting Men Who Should Be Treated
As mentioned above, the foundations of any therapy of osteoporosis are adequate calcium and vitamin D nutrition, safe physical activity, the avoidance of risk factors for bone loss, and the identification and treatment of secondary factors associated with bone disease. What men should be considered for additional pharmacological therapy?
1. Men who are starting long-term supraphysiological doses of glucocorticoids or who will receive androgen ablation therapy for prostate cancer may deserve therapy to prevent rapid bone loss. In these men a reasonable approach is to measure BMD when glucocorticoid or androgen ablation treatment is started. If baseline BMD is low, especially in the presence of previous fracture of other risk factors for bone loss, bisphosphonate treatment should be recommended. If, on the other hand, baseline BMD is well preserved (BMD T-score > )2.0), adequate calcium/vitamin D nutrition and activity should be advised, and BMD reassessed in 12-24 months. If bone loss is found to occur despite conservative measures, bisphosphonate treatment should be considered. 2. Men with low BMD (T-score < )2.0 should be considered candidates for pharmacological treatment). In this category, men who are young, have no previous fractures, have relatively higher levels of BMD, or have no other risk factors for bone loss, might be more appropriately treated with preventive measures while BMD is carefully monitored. In others, therapy is reasonable. 3. There are many other medical conditions, medications, and lifestyle factors that are associated with osteoporosis in men and in which the effectiveness of osteoporosis therapies have not been evaluated. In these cases a strategy similar to that described above for glucocorticoid excess and hypogonadism may be useful. The appropriateness and choice of therapy depends on the specific clinical situation.
The Choice of Specific Therapy
In men there have been no direct comparisons of the effectiveness of the major therapeutic options. In view of the evidence of their efficacy, safety, and ease of administration, bisphosphonates should be the first choice in most clinical situations. Alendronate is the only bisphosphonate that has been adequately tested in men with primary osteoporosis, but other bisphosphonates have been shown to be effective in other situations (e.g., risedronate in glucocorticoid-induced osteoporosis) and there are no compelling reasons to doubt their efficacy. In men in whom bisphosphonates are contraindicated, or have been unsuccessfully used, parathyroid hormone can be considered. Other less well-validated therapies (e.g., calcitonin) also may be useful in limited situations. Since parathyroid hormone therapy is anabolic and probably results in a more robust increase in bone mass, it is currently considered appropriate in patients with more severe osteoporosis, especially those who have already experienced fractures. Again, whether it is more effective in this situation than are other options is unclear.
